Medigen Biotechnology (ROCO:3176) Other Net Income (Loss) : NT$-0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Other Net Income (Loss)?

Medigen Biotechnology's Other Net Income (Loss) for the three months ended in Mar. 2025 was NT$-0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2025 was NT$-0 Mil.

Medigen Biotechnology's quarterly Other Net Income (Loss) declined from Sep. 2024 (NT$0 Mil) to Dec. 2024 (NT$-0 Mil) but then stayed the same from Dec. 2024 (NT$-0 Mil) to Mar. 2025 (NT$-0 Mil).

Medigen Biotechnology Other Net Income (Loss) Historical Data

The historical data trend for Medigen Biotechnology's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Other Net Income (Loss) Chart

Medigen Biotechnology Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Net Income (Loss)

Get a 7-Day Free Trial

Medigen Biotechnology Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Medigen Biotechnology Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0 Mil.

Medigen Biotechnology Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigen Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560

Website

https://www.medigen.com.tw

Medigen Biotechnology Corp is a biopharmaceutical company engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The company has four segments: Nucleic acid department: segment, which derives maximum revenue, is responsible for services of testing reagents, instruments and inspection on behalf of others; New drug and vaccine research and development segment: responsible for the development and relevant services of new drugs and vaccine; Cytotherapy department: responsible for research and development and relevant services of cytotherapy; and Generic drug, aesthetic medicine product and dietary supplement segment is responsible for production and sales and relevant services of western medicine, aesthetic medicine product and dietary supplement.

Medigen Biotechnology Headlines

No Headlines